Berry Gene disclosed on April 30, 2024 in the Shenzhen Stock Exchange that as of April 10, 2024, the number of shareholders of the company was 53,000, a decrease of 4,596 or 7.98% from the previous period (March 31, 2024).
The number of shareholders of Berry Gene is higher than the industry average. According to Choice data, as of April 10, 2024, the average number of shareholders of listed companies in the pharmaceutical and biotechnology industry is 33,900. Among them, the number of shareholders of the company is in the range of 5,000~15,000, accounting for the highest proportion, 28.84%.
Distribution of the number of shareholders in the pharmaceutical and biological industry
Number of shareholders and share price
Since February 8, 2024, the number of shareholders of the company has increased significantly, with an increase of 16.78%. From February 8, 2024 to April 10, 2024, the stock price increased by 34.49%.
Number of shareholders and share price
Number of shareholders and share capital
As of April 10, 2024, the company's latest total share capital is 354 million shares, of which the outstanding share capital is 300 million shares. The average number of outstanding shares held by households increased from 5,212 shares in the previous period to 5,665 shares, and the average market value of households was 48,100 yuan.
The average amount of shares held by each household
The market value of Berry Gene is lower than the industry average. According to Choice data, as of April 10, 2024, the average market value of A-share listed companies in the pharmaceutical and biological industry is 400,300 yuan. Among them, 25.31% of the company's households hold a circulating stock market value in the range of 130,000~250,000.
Distribution of per capita circulating market value of the pharmaceutical and biological industry
Disclaimer: This article is based on big data and is for reference only and does not constitute any investment advice.